Biosimilars May Finally Stop the Rocketing Cost of Insulin

Biosimilars May Finally Stop the Rocketing Cost of Insulin
By

The high cost of insulin is largely due to a lack of competition and too few makers of the current products. One of the best hopes for more affordable insulin is to increase market competition and drive down prices with so-called biosimilar drugs, which are highly similar versions of the original biologic medications – and typically far less expensive.

October 26, 2022 at 11:44PM
via WebMD Health read more...